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1. INTRODUCTION
Human tumours have evolved intricate mechanisms
to evade the immune system, either by avoiding rec-
ognition or by inhibiting and eliminating immune cells.
Although clear evidence exists that the immune sys-
tem is mobilized in response to tumour growth—a fact
that is manifested in the accumulation of numerous
immune cells including dendritic cells (DCs), natural
killer (NK) cells, macrophages, and lymphocytes at the
tumour site—tumour growth continues unabated. One
of the major obstacles to the success of immunotherapy
of cancer is therefore the diminished immune respon-
siveness of cancer patients with progressing disease.
Continued tumour growth in the presence of what
appears to be a significant antitumour response sug-
gests the existence of a microenvironment that is
inhospitable to antitumour immune effector mecha-
nisms. Several tumour-derived products present in sera
and tumour extracts from cancer patients, including
transforming growth factor b (TGFb), prostaglandin E2,
interleukin-10, and vascular endothelial growth fac-
tor 1–4, have been identified and employ a variety of
mechanisms to promote tumour growth.
To develop effective cancer therapy modalities,
an understanding of the biologic effects that these tu-
mour-derived factors have on immune cells is essen-
tial. The challenge, therefore, is to identify the
underlying mechanisms of action of tumour-promot-
ing factors, so that effective counteractive strategies
that will bolster the antitumour immune response can
be developed.
2. DISCUSSION
2.1 TGFb b b b b and Dendritic Cells
One of the most studied and best described tumour-
derived factors with potent immunosuppressive ac-
tivity is TGFb. A pleiotropic cytokine 5, TGFb is secreted
in copious amounts by murine and human cancer cells.
In melanoma and in pancreatic, colorectal, lung, and
breast cancers, elevated levels of circulating TGFb have
been correlated with disease progression, metastases,
disease recurrence, and mortality 6–13. The immuno-
suppressive activities of TGFb include inhibition of the
differentiation and effector functions of T cells, NK
cells, lymphokine-activated killer cells, macrophages,
and DCs 14.
The impact of tumour-derived TGFb on DC func-
tion is of particular interest because of the founda-
tional role that DCs play in the induction of
antigen-specific tumour immunity—especially in the
context of their use as cancer vaccines. Transforming
growth factor b affects DCs in numerous ways that
negatively affect their ability to prime tumour-spe-
cific T cells, including downregulation of cell-surface
major histocompatibility complex (MHC) antigens,
downregulation of co-stimulatory molecules and
chemokine receptors, and impairment of maturation
and migration to secondary lymphoid organs. These
effects are also supported by the reported functional
impairment of circulating and tumour-infiltrating DCs
in tumour-bearing animals and in cancer patients such
that the DCs are unable to induce T-cell responses 15–18.
Given the central role of DCs in inducing antigen-
specific immune responses, the impact of tumour-de-
rived TGFb on DCs poses a major challenge for DC-based
cancer immunotherapy. Therapeutic strategies that can
successfully negate the impact of TGFb on DCs would
therefore be expected to result in enhanced DC func-
tion and to lead to improved clinical responses.
The importance of DC-mediated immune responses
against TGFb-producing tumours can be shown by sys-
temic inhibition of TGFb-mediated signalling using a
TGFb neutralizing antibody in combination with a DC
vaccine or DCs in which TGFb signalling is impaired by
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the expression of a dominant negative TGFb type II re-
ceptor (dnTGFbRII) transgene 15,19 (unpubl. data). These
strategies have enhanced the immune response against
TGFb-producing murine breast cancer and melanoma
respectively. Those results suggest that counteracting
TGFb-mediated signalling in immune cells, including
DCs, may be exploited to enhance antitumour immune
responses. However, tumour cell destruction by the
immune system ultimately depends on an efficient cell-
mediated immune response carried out by CD8+ cyto-
toxic T lymphocytes (CTLs). This process usually
depends on MHC class-II restricted CD4+ T-cell help that
provides the cytokine signals necessary for activation
and clonal expansion of tumour reactive CTLs and for
memory formation that can then provide the much-
desired long-term antitumour protection.
Like DCs, CTLs and CD4+ helper T cells are both
functionally impaired in the presence of TGFb, as evi-
denced by reduced cytokine production and prolifera-
tive potential, blunting the effectiveness of the
cell-mediated immune response. The importance of
this process and the impact of neutralizing the immu-
nosuppressive effects of TGFb on T cells to enhance
an antitumour immune response in vivo has been dem-
onstrated by Flavell’s group. Their studies 19,20 targeted
expression of dnTGFbRII in transgenic mice to
T lymphocytes, leading to immune-mediated rejection
of TGFb-producing EL-4 thymoma and B16 melanoma
tumours. In a study by another group, sub-lethally ir-
radiated mice transplanted with dnTGFbRII-expressing
bone marrow cells demonstrated improved survival
over mice receiving wild-type bone marrow when
challenged with B16 melanoma or TRAMP-C2 prostate
tumours 21. Furthermore, adoptive transfer of tumour-
specific, dnTGFbRII-expressing CD8+ T cells into TRAMP-
C2 tumour-bearing mice led to improved survival and
a reduction in the number of pulmonary metastases 22.
2.2 Novel Human Therapies
Promising findings of augmentation of the antitumour
immune response by inhibition of TGFb leads us to
examine how such augmentation may be translated
into novel human therapies. Although the described
animal models are useful for studying in vivo DC,
T-cell, and TGFb biology, they do not easily lend them-
selves to translation to the clinic for the treatment of
human malignancies. One approach would be to gen-
erate tumour-specific T cells in combination with
antigen-pulsed DCs for adoptive cell transfer (ACT).
Current ACT involves the transfer of either ex vivo
activated T cells or antigen-pulsed DCs into cancer
patients. Adoptive transfer of tumour-specific T cells
has been accomplished by first vaccinating patients
with autologous tumour cells, harvesting the vaccine-
draining lymph node cells, expanding the recovered
lymphocytes ex vivo, and re-infusing the activated
T cells into the patient 23,24. In similar studies, treat-
ment with ex vivo–stimulated tumour-infiltrating
T lymphocytes was well tolerated, and the transferred
T cells persisted in the circulation for several
months 25. The DC-based ACT has used tumour lysate,
tumour antigen, or peptide-pulsed DCs, and has dem-
onstrated robust immunologic antitumour responses
accompanied by modest clinical outcomes in patients
with cancers of various histologic origins 26–29.
These adoptively transferred DCs and T cells
would be expected to encounter significant amounts
of tumour-derived TGFb in the peripheral circulation
and at the tumour site that could impair their ability
to efficiently prime the immune system or mediate
effector functions. A combinatorial approach in which
both DCs and T cells are protected from the deleteri-
ous effects of TGFb would be expected to improve the
therapeutic efficacy of ACT. Several different classes
of TGFb antagonists are now in development, such as
TGFb-neutralizing monoclonal antibodies 30,31, soluble
TbRII:Fc fusion proteins, and antisense TGFb oligo-
nucleotides 32,33.
Of particular interest is the recent development
of small-molecule TGFb receptor kinase inhibitors.
These molecules resemble dnTGFbRII expression in that
they inhibit TGFb-mediated signalling at the cellular
level 34–36. They are particularly promising because
of their ease of manufacture and use as compared with
larger-molecular therapeutics such as antibodies.
3. CONCLUSION
The observations presented here show that therapeutic
approaches that neutralize or abrogate tumour-derived
products such as TGFb significantly enhance the effec-
tor activity of immunocytes in the tumour microenvi-
ronment. Studies are underway to combine these novel
anti-TGFb therapies with adoptive cell transfer to de-
vise better therapeutic approaches that, in conjunction
with established treatments, will provide oncologists
with additional therapeutic options in the future.
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